Form 4: CalciMedica CFO Stephen Bardin Reports Stock Option Grant
SEC Form 4 Filing
CalciMedica's Chief Financial Officer, Stephen Bardin, reports the acquisition of stock options.
Summary
- Stephen Bardin, CFO of CalciMedica, Inc., filed a Form 4 on April 25, 2025, reporting a transaction.
- The transaction involved the acquisition of employee stock options (right to buy) for 130,000 shares of common stock at an exercise price of $1.53 per share.
- The options were granted on April 23, 2025, and vest in equal monthly installments over a four-year period, beginning March 26, 2025.
- The expiration date for these options is April 22, 2035.
- Following the reported transaction, Bardin directly owns derivative securities for 130,000 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting a stable and incentivized management team. This is generally viewed positively.
Positives
- The grant of stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
- Companies like Amgen, Gilead, and Biogen routinely use stock options as part of their executive compensation strategy.
- The vesting schedule and exercise price are generally determined based on industry standards and the company's specific circumstances.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/23/2025 | Date of earliest transaction (grant date of stock options) |
| 03/26/2025 | Beginning of vesting period for the stock options |
| 04/22/2035 | Expiration date of the stock options |
| 04/25/2025 | Date of Form 4 filing |
Keywords
Form 4, Stock Options, CalciMedica, Bardin, CFO, Equity, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.